Compare BIIB Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Biogen
It's a definite maybe.
The stock has a tough road back to $400, assuming it can get back there at all.
The company is moving into three billion-dollar areas.
BIIB earnings call for the period ending June 30, 2021.
This biotech company could be a diamond in the rough -- for investors who can tolerate its share price volatility.
Both are making Alzheimer's drugs, but only one can claim success as of today.
The company faces hard questions from a House committee about the pricing of Alzheimer's disease drug Aduhelm.
Even with markets suffering, there were still some positives on Wall Street.
A nonprofit group doesn't like a recent move by Biogen.